FDA 실무 그룹 리더인 데이비드 로젠이 10월 1일에 열리는 SAAMnow의 가을 워크숍에서 "API 및 의약품의 N-니트로사민 불순물을 둘러싼 소용돌이 탐색" 세션에서 발표합니다.
The workshop will focus on regulatory, scientific, and technical challenges surrounding the presence of N-nitrosamine impurities in active pharmaceutical ingredients (APIs) and drug products. Participants will explore cutting-edge methods, regulatory updates, and research developments regarding N-nitrosamines.
The workshop will address:
- U.S. Food and Drug Administration (FDA) perspective on N-Nitrosamine Impurities,
- International Generic and Biosimilar Medicines Association (IGBA) perspective on nitrosamine impurities, the worldwide challenges,
- ICH M7 risk assessment and control of N-nitrosamine impurities,
- Over-the counter (OTC) drug products and their challenges with N-nitrosamine impurities, and
- Prescription drug products and their challenges with N-Nitrosamine impurities.
사람
관련 인사이트
December 10, 2025
Foley Viewpoints
NAIC Fall Meeting Update: Mental Health Parity and Addiction Equity Act (B) Working Group
The Mental Health Parity and Addiction Equity Act (B) Working Group (the “Working Group”) monitors developments related to the Mental…
December 10, 2025
Manufacturing Industry Advisor
The Auto Industry’s Talent War: Winning the Race for Skilled Workers
For over a century, the automotive sector was defined by mechanical engineering, fabrication, and assembly line mastery. But today, the industry is undergoing a technological transformation so profound it is rewriting the DNA of car manufacturing.
December 10, 2025
Foley Viewpoints
NAIC Fall Meeting Update: Climate and Resiliency (EX) Task Force
The mission of the Climate and Resiliency (EX) Task Force is to serve as the coordinating NAIC body for discussion and engagement on…